The Silver Lining-Trends in Life Sciences for the Remainder of 2026

Key takeaways

• Investors and buyers are prioritizing mature, commercially validated companies with sustainable revenue and low R&D risk.
• Biotech is leading the IPO reopening, M&A is recovering, and PE/strategic buyers are offering equity deals as an alternative to going public.
• IPO, funding, and M&A conditions are favorable through the second half of 2026 but short-lived, so companies need to move fast.
• Acquirers want to grow revenue/EBITDA, replace products facing patent expiration, and fill pipelines with later-stage candidates while cutting other costs.
• Transaction readiness is the deciding factor. Audit-ready financials, a QoE study, a clean cap table, and a ready data room are essential to move fast when opportunity strikes.

The outlook for life sciences capital markets activity for the second half of 2026 continues to remain positive after a fruitful first half of the year headlined from robust biotech IPOs, venture financing, and select M&A activity.

Looking ahead, later-stage biotech and select platform businesses are expected to see continued IPO activity. A small number of profitable, near-commercial medtech and tools companies with differentiated products might also benefit from expansion. Healthy private equity activity is anticipated for large, later-stage rounds, while early-stage venture and corporate investors are expected to fund but on tougher, more dilutive terms. M&A is likely to remain strong, with strategic buyers targeting late-stage biotech assets, scalable medtech platforms, AI-enabled diagnostics, and contract development manufacturing organization (CDMO) capacity. Finally, windows are projected to open but will not stay open long, favoring companies that are prepared to act quickly over those that are not.

Regardless of the life sciences subsector, in order for companies to be IPO and M&A ready, it is critical companies have their financials in order in advance of a transaction. This article will discuss how life sciences companies can be transaction-ready, along with factors influencing funding activity.

Transaction Readiness for Life Sciences Companies

There are a number of steps life sciences companies can take to support transaction readiness. This includes financial statement and audit preparedness, including PCAOB-ready audits where relevant, reliable interim monthly financials consistent with GAAP, QoE studies, normalized net working capital and debt/debt-like item analyses, interim monthly compliance with GAAP accounting, legal contract and internal controls reviews, virtual data room population, selection of qualified transaction professionals, and disciplined, complete monthly close processes.

Life sciences companies should also confirm that their equity and capital structure are supported with proper accounting for revenue recognition, cost capitalization, full accrual accounting matching revenue with related expenses, preferred stock warrants, SAFEs, and stock-based compensation, as well as clean capitalization tables and defensible valuation support.

Life sciences companies should also have robust governance and execution infrastructure. Some key areas include internal control documentation, SOX readiness, remediation of control gaps, and scalable finance processes, all of which become more important as a company approaches an IPO or prepares for a strategic M&A transaction. For medtech, diagnostics, tools, and services companies in particular, contracting and revenue recognition are key since customer and partner arrangements can materially affect reported performance and diligence outcomes.

Finally, transaction readiness requires well-organized operations: diligence-ready data rooms, documented accounting policies, and clear alignment among finance, legal, and operational teams. Companies often underestimate the time, cost, and increased standards required to achieve audit and SEC/M&A readiness, particularly in technical accounting, internal controls, and financial statement preparation.

Factors Influencing Funding Activity

Several factors are influencing funding activity across the life sciences industry:

• Public market performance has improved. Biotech indices such as XBI increased by approximately 30% in the first half of 2026, helping to reopen the capital markets backdrop. Although better public market performance does not guarantee smooth execution, it does help improve sentiment and valuation support for both public and private financings.
• Large-cap life sciences companies continue to seek external innovation across therapeutics, devices and platforms, and data and diagnostics. For these global companies, it is often less risky to buy products and/or businesses that are more turnkey in nature, rather than risk the time and money to develop new products/product lines organically.
• Clinical and regulatory momentum continues to matter. FDA approvals remained active, with 46 novel drug approvals in 2025 and continued approvals in 2026, reinforcing the importance of milestone-driven value creation.
• Macroeconomic conditions still impose discipline. Interest rates remained elevated at approximately 3.50% to 3.75% as of mid-2026, and the higher cost of capital continues to pressure valuations, financing structures, and investor return expectations.

Closing Thoughts

The life sciences funding environment heading in the second half of 2026 remains positive, so companies need to have their financials in place for an IPO or sale.

Biotech’s IPO momentum, resilient venture funding, and strong M&A activity in both biopharma and medtech all show signs that capital is available to be deployed. However, investors remain more selective, and prefer companies that can demonstrate validated science, commercial traction, or clear strategic value.

As windows for IPOs, funding, and M&A open and close quickly, the companies best positioned to benefit will be those that have already done the work: audit-ready financials, clean cap tables, QoE reports, strong governance, and diligence-ready data rooms.

For further discussion on how EisnerAmper can help your life sciences company get ready for a transaction, please use the form to contact our team.